Research Information Disclosure

TRC-004-01-c
August 7, 2025

Written consent required

This study analyzes aging-related gene expression and DNA methylation to classify aging into specific types (such as inflammation, oxidative stress, low metabolic function, and low immune function). The goal is to create a model to evaluate preventive treatments.

Adults aged 18 and older who received an explanation of the study and gave written consent. This includes patients requesting self-pay testing at Tokyo Relife Clinic and healthy volunteers.

• Blood (including peripheral blood mononuclear cells)
• Saliva
• Skin cells
• Oral mucosal cells (mouth cheek cells)
• Basic profile information (such as age and biological sex)
As a general rule, individual test results will not be shared with participants.

Yoshiyasu Shinohara, MD, PhD (or Title)
Head of Research Division

October 1, 2026 – September 30, 2031

None

TRC-005-01-a
August 29, 2025

Opt-out
(Public disclosure on this website in place of individual consent)

This study reviews medical records of patients who received adipose-derived stem cell therapy at Tokyo Relife Clinic. The goal is to evaluate treatment safety and how symptoms changed before and after treatment for different medical conditions.

Patients aged 40 to 69 who received adipose-derived stem cell therapy at Tokyo Relife Clinic between January and October 2025, and experienced any of the following:
• Menopausal / Andropause symptoms
• Chronic pain
• Diabetes
• Frailty (Sarcopenia)
• Liver dysfunction
• Cerebrovascular disease (stroke-related conditions)
• Hair thinning
• Osteoarthritis
• Erectile dysfunction (ED)

• Age, current medical conditions, and past medical history, treatment and medication details, Symptom evaluation scores, blood test results (routine tests, hormones, oxidative stress markers, etc.), urine test results (routine urinalysis and urinary indole tests), AGEs test results, physical measurements (grip strength and body composition), side effects and adverse events

Yoshiyasu Shinohara (Head of Research Division)

October 1, 2026 – September 30, 2031

None

TRC-006-02-b (February 5, 2026)

• Prospective study: Written consent required
• Retrospective study: Opt-out (public disclosure on this website in place of individual consent)

This study evaluates the safety of iPSC-derived exosomes given through intranasal administration. It also looks at changes in cognition, immune aging markers, and muscle strength in people who received this treatment.

• Prospective study: Adults aged 50 to 80 who received an explanation of the study and gave written consent.
• Retrospective study: Patients aged 50 to 80 who received intranasal iPSC-derived exosome treatment at Tokyo Relife Clinic between October 2025 and late February 2026, and completed health evaluations before and after treatment.

• Age, biological sex, medical history, and current/past medications
• Cognitive tests: MMSE, MoCA-J, MIRUDAKE
• Muscle and physical function tests: Grip strength, walking speed, five-times sit-to-stand test, SARC-F questionnaire
• Blood tests: General blood and biochemical tests, CRP, oxidative stress markers, immune cell analysis, cytokine levels, and AGE scan
• Administration details and any reported side effects / adverse events

Maki Nakao (General Director)

October 1, 2026 – September 30, 2031

Some sample analyses were previously outsourced to partner testing laboratories in Japan and overseas (including Kenko Life Science Inc. and RayBiotech, Inc. [USA]). No additional samples or personal data will be sent to external institutions for this study.
Study findings may be shared with the XPRIZE competition (an international science and technology award). Only group-level (aggregated) data that cannot identify any individual will be used; no personal or individual data will be shared.

TRC-007-01-c (September 3, 2026)

• New samples: Written consent required
• Existing samples: Opt-out (public disclosure on this website in place of individual consent)

This study investigates how aging works, focusing on how aging in adipose-derived stem cells relates to age-related conditions. The goal is to help develop new ways to diagnose, prevent, and treat aging.

• New samples: Individuals who agree to provide blood, urine, or adipose-derived stem cells for research and give written consent.
• Existing samples: Patients whose leftover samples (including blood, urine, adipose tissue, or other cells collected during regular care at Tokyo Relife Clinic) are currently stored.

• The biological samples listed above
• Clinical information (age, biological sex, test results, etc.)
• Laboratory analyses: Gene expression, DNA methylation, proteins and metabolites, cellular aging markers, and stem cell quality evaluations
Note: Existing samples will not be used until 14 days after this notice is published (use begins on or after October 16, 2026).

Yoshiyasu Shinohara (Head of Research Division)

From Ethics Review Committee approval date to March 31, 2036

Samples and data may be shared with universities, research institutes, medical centers, and companies in Japan.
Medical records will not be shared with outside recipients.
If samples or data are ever shared with overseas institutions, separate written consent will be obtained in advance.

TRC-008-01-c (September 3, 2026)

Written consent required

This study tests how reliably stem cells can be collected from urine. The goal is to set quality standards for these cells and better understand their biological characteristics.

Healthy adult volunteers aged 20 to 64 who received an explanation of the study and gave written consent.

• Urine samples (collected by the participant, usually three times)
• Questionnaire data: Age, biological sex, height, weight, medical history, and current/past medications
Note: No blood samples are collected for this study.

Yoshiyasu Shinohara (Head of Research Division)

From Ethics Review Committee approval date to March 31, 2036

Samples and personal data will not be shared with outside institutions. Some specialized tests that cannot be done at Tokyo Relife Clinic may be outsourced to partner laboratories. In these cases, names and any identifying information will never be shared with contractors.

TRC-009-01-c (September 3, 2026)

Written consent required

This study evaluates the laboratory methods used at Tokyo Relife Clinic to separate and grow immune cells from blood, as well as the standards used to check their quality.
Note: Cells grown in this study will not be administered to humans.

• Adults aged 20 and older who received an explanation of the study and gave written consent
• Patients receiving autologous immune cell therapy at Tokyo Relife Clinic

• Blood samples (collected specifically for research from healthy volunteers; leftover blood from regular cell processing used for therapy patients)
• Basic profile information (such as age and biological sex)
• Cell processing and culture records

Yoshiyasu Shinohara (Head of Research Division)

From Ethics Review Committee approval date to March 31, 2036

Samples and personal data will not be shared with outside institutions. Some specialized tests that cannot be done at Tokyo Relife Clinic may be outsourced to partner laboratories. In these cases, names and any identifying information will never be shared with contractors.

TRC-010-01-a (September 3, 2026)

Opt-out
(Public disclosure on this website in place of individual consent)

This study reviews medical records of patients who received intravenous (IV) stem cell culture supernatant or exosomes. The goal is to evaluate and compare the safety and effectiveness of each treatment.

Patients aged 30 to 75 who experienced unexplained symptoms for at least one year and received IV stem cell culture supernatant or exosomes during regular care at Tokyo Relife Clinic between April 1, 2024, and September 30, 2025.

• Basic profile: Biological sex, age, height, weight, medical history, existing conditions, and current/past treatments and medications
• Clinical tests: Routine blood tests, oxidative stress tests, urinary indole tests, AGEs tests, body composition, and EpiClock test (measures biological age using DNA methylation)
• Questionnaires: Unexplained symptoms survey, PHQ-9 (mood/depression screening), and PHQ-15 (physical symptoms screening)
• Other details: Administration details and any reported side effects / adverse events

Principal Investigator:
Yoshiyasu Shinohara (Head of Research Division)
Sub-Investigators:
• Maki Nakao (General Director)
• Hidekazu Yamada (Senior Advisor, Anti-Aging Medicine)

October 1, 2026 – September 30, 2031

None

TRC-011-01-b (September 3, 2026)

Opt-out
(Public disclosure on this website in place of individual consent)

This study compares the safety and cosmetic results of three anti-aging facial treatments: adipose-derived culture supernatant, umbilical cord-derived culture supernatant, and skin-booster (water-light) injections using hyaluronic acid.

Women aged 40 to 69 who received any of the treatments listed above for facial aesthetic care at Tokyo Relife Clinic between April 2024 and October 2025.

• Patient background information
• Treatment details (type of procedure, number of sessions, and timing)
• Skin test data (VISIA analysis scores, skin moisture and elasticity test results)
• Skin check sheets
• Adverse events (side effects)
Note: Facial photographs will not be used for this study.

Yoshiyasu Shinohara (Head of Research Division)

October 1, 2026 – September 30, 2031

None

TOKYO RELIFE CLINIC
Toraya Ginza Building 6F, 7F & 8F, 7-8-17 Ginza, Chuo-ku, Tokyo 104-0061, Japan

All samples and data are assigned anonymous research ID codes. Direct identifying information, such as names and addresses, will never be included in the research dataset.
The key code linking these IDs to individual patient names is securely stored by the Principal Investigator in a locked location or in password-protected, access-restricted digital files.

Study results will be presented at medical conferences and published in scientific journals. No personal information that could identify any individual will ever be published.

Requests to opt out may be made by the patient or by an authorized family member or legal representative.
You can submit a request by providing the "Participation Refusal / Opt-Out Request Form," or simply by calling or emailing us.
Once a request is received, the patient's data and samples will be promptly removed from the study. However, data that has already been analyzed, presented at conferences, or published in papers cannot be withdrawn.
Note: For studies where written consent was previously signed, consent may be withdrawn at any time.

Research protocols and study materials can be reviewed upon request, as long as the review does not violate anyone's personal privacy or disrupt the progress of the study.

Research Office, TOKYO RELIFE CLINIC
• Phone: +81-120-660-329 (Toll-Free in Japan: 0120-660-329)
• Email: info@tokyorelife.com
• Office Hours: 10:00 – 19:00 (JST)